anti 5t4 antibody drug conjugate pf 06263507

Drug Overview

anti 5t4 antibody drug conjugate pf 06263507 (also known as A1mcMMAF) is an investigational precision therapy designed to treat advanced solid tumors. It is a “guided missile” that combines a monoclonal antibody with a potent cell-killing agent. Its mission is to seek out a specific protein called 5T4 (trophoblast glycoprotein), which is heavily present on the surface of many cancer cells but rare in healthy adult tissues.

In clinical oncology, PF-06263507 is classified as an Antibody-Drug Conjugate (ADC). It was developed to overcome the limitations of standard chemotherapy by delivering a toxic payload directly inside the tumor cell, theoretically reducing damage to the rest of the body.

• Generic Name: Anti-5T4 antibody-drug conjugate PF-06263507.
• Drug Class: Antibody-Drug Conjugate (ADC) / Microtubule Inhibitor.
• Target: 5T4 oncofetal antigen (Trophoblast glycoprotein).
• Route of Administration: Intravenous (IV) infusion.
• Developer: Pfizer.
• Status: Discontinued. As of 2026, clinical development for this specific agent has been terminated. While it provided valuable data for the “next generation” of 5T4-targeting drugs, it is no longer being pursued as a standalone treatment due to safety and efficacy results in Phase I trials.

What Is It and How Does It Work? (Mechanism of Action)

The 5T4 Targeting Strategy

The 5T4 antigen is a protein that is usually only found in a developing fetus. However, many cancers “turn it back on” to help the tumor grow and invade other tissues. Because healthy adult cells rarely have this protein, it serves as an ideal “ZIP code” for the drug to find.

Molecular Level Mechanisms

1. Selective Binding: The antibody portion of the drug circulates in the blood until it encounters a cell expressing 5T4. It locks onto the antigen with high precision.
2. Internalization: Once the drug attaches to the surface, the cancer cell “swallows” the entire complex through a process called endocytosis.
3. Payload Release: Inside the cell, the drug is moved to the lysosome (the cell’s recycling center). Here, enzymes break the linker, releasing the active toxin, MMAF, into the cell’s interior.
4. Microtubule Disruption: MMAF is a powerful microtubule inhibitor. It prevents the cell from building the internal “skeleton” it needs to divide. This causes the cell to freeze during division (G2/M phase arrest) and eventually commit “programmed suicide” (apoptosis).

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for PF-06263507.

As of 2026, PF-06263507 remains an unapproved investigational agent. Clinical development was discontinued by Pfizer after Phase I trials failed to show significant antitumor activity and revealed limiting toxicities.

Investigational Focus (Prior to Discontinuation):

During its development, the drug was investigated for the treatment of locally advanced or metastatic solid tumors that were unresponsive to standard therapy. The research specifically targeted:

• Non-Small Cell Lung Cancer (NSCLC)
• Breast Cancer
• Ovarian Cancer

Note: Because 5T4 is an “oncofetal” antigen (expressed widely in tumors but rarely in healthy adults), the drug was intended as a broad-spectrum treatment for any 5T4-positive solid malignancy.

Dosage and Administration Protocols

Because the drug did not move past Phase I, there is no “standard” clinical dose. The following protocols were established during the dose-escalation study (NCT01891669).

Clinical Trial Dosage

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for PF-06263507.

As of 2026, PF-06263507 remains an unapproved investigational agent. Clinical development was discontinued by Pfizer after Phase I trials failed to show significant antitumor activity and revealed limiting toxicities.

Investigational Focus (Prior to Discontinuation):

During its development, the drug was investigated for the treatment of locally advanced or metastatic solid tumors that were unresponsive to standard therapy. The research specifically targeted:

• Non-Small Cell Lung Cancer (NSCLC)
• Breast Cancer
• Ovarian Cancer

Note: Because 5T4 is an “oncofetal” antigen (expressed widely in tumors but rarely in healthy adults), the drug was intended as a broad-spectrum treatment for any 5T4-positive solid malignancy.

Dosage and Administration Protocols

Because the drug did not move past Phase I, there is no “standard” clinical dose. The following protocols were established during the dose-escalation study (NCT01891669).

Clinical Trial Dosage

Administration Guidelines

• Baseline Assessments: Patients required extensive ophthalmological exams (slit-lamp, visual acuity) before each dose due to the risk of corneal damage.
• Cycle Duration: One cycle consisted of 21 days. Dose escalation was determined by a “modified continual reassessment method” to find the safest effective amount.
  +1
• Dose Modifications: In the trial, doses were delayed or reduced specifically if Ocular Toxicity (Grade 2 or higher keratitis) or Neutropenia occurred during the first 21-day window.

Why was it discontinued?

While the MTD was found to be 4.34 mg/kg, the drug was eventually shelved because:

1. Low Efficacy: No “objective responses” (significant tumor shrinkage) were observed in the human subjects at any dose level.
2. Ocular Safety: The toxic payload (MMAF) caused significant eye issues, including limbal stem cell deficiency, which made higher, potentially effective doses too dangerous for the patients’ vision.

Clinical Status and Efficacy

Although PF-06263507 showed significant promise in animal models (preclinical trials), its performance in human trials led to its discontinuation.

Research Results (NCT01891669)

• Patient Population: The Phase I trial included patients with advanced solid tumors, including lung, breast, ovarian, and colorectal cancers.
• Objective Response: In the dose-escalation study, no objective responses (significant tumor shrinkage) were observed in the 26 patients treated, even at the highest doses.
• Pharmacokinetics: The drug showed a dose-related increase in exposure, but it did not translate into the level of anti-tumor activity expected from preclinical data.

Safety Profile and Side Effects

The primary reason for the challenges in developing PF-06263507 was a specific type of side effect involving the eyes, which is a known risk for drugs using the MMAF payload.

Common Side Effects:

• Fatigue: Reported by nearly 40% of patients.
• Nausea and Decreased Appetite: Common gastrointestinal complaints.
• Thrombocytopenia: A drop in platelet counts, which can affect blood clotting.

Serious/Dose-Limiting Toxicities (DLTs):

• Ocular Toxicity: This was the most significant hurdle. Patients experienced photophobia (light sensitivity), keratitis (inflammation of the cornea), and dry eye.
• Limbal Stem Cell Deficiency: In higher doses, some patients experienced damage to the stem cells responsible for regenerating the surface of the eye, leading to treatment delays.

The Future of 5T4 Research

While PF-06263507 itself is no longer in development, the 5T4 protein remains a high-interest target in Regenerative Medicine and Oncology. Researchers are using the lessons learned from this drug to develop safer alternatives:

• CAR-T Therapy: Scientists are engineering “soldier” T-cells to recognize 5T4 and destroy cancer cells directly.
• Newer ADCs: New 5T4-targeting drugs (like ASN004 and XB010) are using different linkers and “payloads” designed to avoid the eye toxicities seen with PF-06263507 while providing stronger tumor-killing power.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. PF-06263507 is a discontinued investigational agent and is not available for clinical use. Always consult with your oncologist regarding currently approved therapies or active clinical trials.